<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585479</url>
  </required_header>
  <id_info>
    <org_study_id>TA-C/Ahcc</org_study_id>
    <nct_id>NCT02585479</nct_id>
  </id_info>
  <brief_title>Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma</brief_title>
  <official_title>Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that systemic chemotherapy is superior to
      transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in
      patients with Advanced Hepatocellular Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression within liver</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression outside the liver</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>systemic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin</intervention_name>
    <description>Pirarubicin 30mg/m2 intravenously
Pirarubicin17mg/m2 are infused through the right and left hepatic arteries</description>
    <arm_group_label>systemic chemotherapy</arm_group_label>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 100 mg/m2 intravenously
Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries</description>
    <arm_group_label>systemic chemotherapy</arm_group_label>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipiodol</intervention_name>
    <description>Lipiodol 5-10ml infused through the right and left hepatic arteries</description>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelfoam</intervention_name>
    <description>Hepatic artery embolization with Gelfoam.</description>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients were age 18 to 75 years;

          -  The patients had histologically, cytologically,or clinically diagnosed unresectable
             HCC;and were ineligible for local invasive treatment. Clinically diagnosed patients
             had to have: (1) evidence of HBV or HCV with hepatic cirrhosis; (2) a-fetoprotein
             levels 400g/L; and (3) morphologic evidence of hypervascular liver tumor. Patients had
             to have at least one measurable lesion according to RECIST (version 1.0; ≥2 cm on
             computed tomography [CT]; 1 cm on spiral CT or magnetic resonance imaging). Lesions
             that had undergone previous interventional or local therapy were not considered
             measurable lesions.

          -  ECOG score≤2;

          -  life expectancy 3 months;

          -  Barcelona Clinic liver cancer (BCLC) stage B or C disease;

          -  Child-Pugh stage A or B disease;

          -  Adequate organ and marrow function, with neutrophil count≥1.5X10e9/L, platelet
             count≥75×10e9/L, AST or ALT﹤2.5×upper limit of normal (ULN), total bilirubin

             ＜1.5×ULN, international normalized ratio ＜1.5;normal baseline left ventricular
             ejection fraction_lower limit of normal for the institution. Patients with AST and
             ALT＜5 ×ULN could be recruited if total bilirubin was in the normal range.

          -  Patients had to provide signed informed consent to participate.

        Exclusion Criteria:

          -  documented allergy to lipoidal or other study drugs; any previous treatment before
             random assignment;

          -  Previous liver transplantation;

          -  concomitant use of any other anticancer therapy, including interferon alfa and herbal
             medicine approved by the local authority to be used as anticancer medicine (except
             palliative radiotherapy to a nontarget lesion);

          -  CNS metastasis;

          -  Other serious illness or medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lequn Li, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Tumor Hospital, Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chengcheng Liao, MD</last_name>
    <phone>+8615907817794</phone>
    <email>148804@qq.com</email>
  </overall_contact>
  <reference>
    <citation>Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.</citation>
    <PMID>23980077</PMID>
  </reference>
  <reference>
    <citation>Li L, Sun F, Chen AJ, Li XY, Hu MD, Ran JH, Tang JH. [Capecitabine combined with TACE for advanced liver cancer]. Zhonghua Zhong Liu Za Zhi. 2004 Sep;26(9):565-6. Chinese.</citation>
    <PMID>15555291</PMID>
  </reference>
  <reference>
    <citation>Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.</citation>
    <PMID>19453695</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Chengcheng Liao</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

